D Sánchez-Infantes1, J M Gallego-Escuredo2, M Díaz1, G Aragonés3, G Sebastiani1, A López-Bermejo4, F de Zegher5, P Domingo6, F Villarroya2, L Ibáñez1. 1. 1] Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain [2] Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, Madrid, Spain. 2. 1] Department of Biochemistry and Molecular Biology and Institute of Biomedicine, University of Barcelona, Barcelona, Spain [2] Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN), ISCIII, Madrid, Spain. 3. Department of Medicine & Surgery, Universitat Rovira i Virgili (URV), Tarragona, Spain. 4. 1] Department of Pediatrics, Dr. Josep Trueta Hospital, Girona, Spain [2] Girona Institute for Biomedical Research, Girona, Spain. 5. Department of Development and Regeneration, University of Leuven, Leuven, Belgium. 6. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Abstract
BACKGROUND/ OBJECTIVE: Fibroblast growth factor 19 (FGF19) and 21 (FGF21) have been linked to obesity and type 2 diabetes in adults. We assessed the circulating concentrations of these factors in human neonates and infants, and their association with the endocrine-metabolic changes associated to prenatal growth restraint. SUBJECTS/ METHODS: Circulating FGF19 and FGF21, selected hormones (insulin, insulin-like growth factor I and high- molecular-weight (HMW) adiponectin) and body composition (absorptiometry) were assessed longitudinally in 44 infants born appropriate- (AGA) or small-for-gestational-age (SGA). Measurements were performed at 0, 4 and 12 months in AGA infants; at 0 and 4 months in SGA infants; and cross-sectionally in 11 first-week AGA newborns. RESULTS: Circulating FGF19 and FGF21 surged >10-fold in early infancy from infra- to supra-adult concentrations, the FGF19 surge appearing slower and more pronounced than the FGF21 surge. Whereas the FGF21 surge was of similar magnitude in AGA and SGA infants, FGF19 induction was significantly reduced in SGA infants. In AGA and SGA infants, cord-blood FGF21 and serum FGF19 at 4 months showed a positive correlation with HMW adiponectin (r=0.49, P=0.013; r=0.43, P=0.019, respectively). CONCLUSIONS: Our results suggest that these early FGF19 and FGF21 surges are of a physiological relevance that warrants further delineation and that may extend beyond infancy.
BACKGROUND/ OBJECTIVE:Fibroblast growth factor 19 (FGF19) and 21 (FGF21) have been linked to obesity and type 2 diabetes in adults. We assessed the circulating concentrations of these factors in human neonates and infants, and their association with the endocrine-metabolic changes associated to prenatal growth restraint. SUBJECTS/ METHODS: Circulating FGF19 and FGF21, selected hormones (insulin, insulin-like growth factor I and high- molecular-weight (HMW) adiponectin) and body composition (absorptiometry) were assessed longitudinally in 44 infants born appropriate- (AGA) or small-for-gestational-age (SGA). Measurements were performed at 0, 4 and 12 months in AGA infants; at 0 and 4 months in SGA infants; and cross-sectionally in 11 first-week AGA newborns. RESULTS: Circulating FGF19 and FGF21 surged >10-fold in early infancy from infra- to supra-adult concentrations, the FGF19 surge appearing slower and more pronounced than the FGF21 surge. Whereas the FGF21 surge was of similar magnitude in AGA and SGA infants, FGF19 induction was significantly reduced in SGA infants. In AGA and SGA infants, cord-blood FGF21 and serum FGF19 at 4 months showed a positive correlation with HMW adiponectin (r=0.49, P=0.013; r=0.43, P=0.019, respectively). CONCLUSIONS: Our results suggest that these early FGF19 and FGF21 surges are of a physiological relevance that warrants further delineation and that may extend beyond infancy.
Authors: Gregory Gaich; Jenny Y Chien; Haoda Fu; Leonard C Glass; Mark A Deeg; William L Holland; Alexei Kharitonenkov; Thomas Bumol; Holger K Schilske; David E Moller Journal: Cell Metab Date: 2013-09-03 Impact factor: 27.287
Authors: Fredirick L Mashili; Reginald L Austin; Atul S Deshmukh; Tomas Fritz; Kenneth Caidahl; Katrin Bergdahl; Juleen R Zierath; Alexander V Chibalin; David E Moller; Alexei Kharitonenkov; Anna Krook Journal: Diabetes Metab Res Rev Date: 2011-03 Impact factor: 4.876
Authors: Serkan Kir; Sara A Beddow; Varman T Samuel; Paul Miller; Stephen F Previs; Kelly Suino-Powell; H Eric Xu; Gerald I Shulman; Steven A Kliewer; David J Mangelsdorf Journal: Science Date: 2011-03-25 Impact factor: 47.728
Authors: Glenn S Gerhard; Amanda M Styer; G Craig Wood; Stephen L Roesch; Anthony T Petrick; Jon Gabrielsen; William E Strodel; Christopher D Still; George Argyropoulos Journal: Diabetes Care Date: 2013-07 Impact factor: 19.112
Authors: Alberto O Chavez; Marjorie Molina-Carrion; Muhammad A Abdul-Ghani; Franco Folli; Ralph A Defronzo; Devjit Tripathy Journal: Diabetes Care Date: 2009-06-01 Impact factor: 19.112
Authors: Naureen Memon; Ian J Griffin; Chris W Lee; Aimee Herdt; Barry I Weinberger; Thomas Hegyi; Mary O Carayannopoulos; Lauren M Aleksunes; Grace L Guo Journal: J Matern Fetal Neonatal Med Date: 2018-10-29